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Summary: The mechanisms of action of antiepileptic 
drugs effective against generalized absence seizures 
(antiabsence AEDs) remain uncertain. Antiabsence 
AEDs are generally effective against seizures induced in 
experimental animals by pentylenetetrazol (PTZ) and 
methyl~,7-dimethoxy~-ethyl-~-carboline-3-c~boxy~ate 
(DMCM), drugs which reduce GABAergic inhibition. 
Thus, antiabsence AEDs have been suggested to enhance 
GABAergic inhibition. We studied the effects of several 
AEDs on GABA responses recorded from mouse spinal 
cord neurons grown in primary dissociated cell culture. 
Four antiabsence AEDs were included: ethosuximide 
(ESM), dimethadione (DMO), sodium valproate (VPA), 
and diazepam (DZP). Two experimental AEDs, CGS 
98% and ZK 912%, with anticonvulsant action against 
PTZ- or DMCM-induced seizures were also included. 
Possible effects of the antiabsence and experimental 
AEDS on PTZ- and DMCM-induced inhibition of GABA 
responses were also evaluated. PTZ and DMCM revers- 
ibly reduced GABA responses in a concentration- 
dependent manner. PTZ completely inhibited GABA re- 
sponses at 10 mM (ICso of 1 . 1  mM), whereas DMCM- 
induced inhibition of GABA responses reached a plateau 
level of 39% of control values at 1 p M  (ICso of 33 nM). 
ESM (1,200 p m ,  DMO (6 mM), VPA (200 pM), CGS 
98% (2 pM), and ZK 98% (2 pM) did not alter GABA 
responses. DZP enhanced GABA responses in a concen- 
tration-dependent manner. The inhibition of GABA re- 
sponses produced by PTZ 1 mM was unaltered by ESM 
(600 pi'@), DMO (6 mM), CGS 98% (1 pkf), or ZK 98% 
(1 pM). Coapplication of VPA (200 pM) and PTZ (1 mM) 
slightly enhanced the FTZ effect. DZP (>lo nM), how- 
ever, reversed the PTZ-induced reduction of GABA re- 
sponses. The DMCM (250 nM) inhibition of GABA- 
responses was unaltered by ESM (600 pw, DMO 
(2 mM), or VPA (200 pM). CGS 98% (2 pM) and ZK 
912% (2 pM), however, antagonized the DMCM effect. 
DZP (> 10 nM) significantly reversed the DMCM-induced 
inhibition of GABA responses. The lack of effect of VPA, 
ESM, and DMO on postsynaptic GABA responses sug- 
gests that direct enhancement of postsynaptic GABA ac- 
tion is not a common mechanism of action of antiabsence 
AEDs. The AEDs DZP, CGS 9896, and ZK 912% all 
reversed DMCM, but not PTZ, reduction of GABA re- 
sponses, suggesting that these AEDs blocked DMCM sei- 
zures by acting at benzodiazepine receptors. However, 
since only DZP enhanced GABA responses, it is unclear 
how CGS 98% and ZK 912% blocked PTZ seizures. Key 
Words: Anticonvulsants-GABA-Neuron culture-cell 
culture-Spinal cord neurons-Convulsants. 
A reduction in central nervous system (CNS) 
GABAergic inhibition has been suggested to be a 
cause of epilepsy (Meldrum, 1979; Roberts, 1980; 
Lloyd et al., 1981; Olsen, 1981), and it has been 
suggested that the mechanism of action of antiepi- 
leptic drugs (AEDs) used in the treatment of gener- 
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alized absence seizures (antiabsence AEDs) may in- 
volve enhancement of GABAergic inhibition (Mac- 
donald and McLean, 1986). 
The GABAA receptor is an oligomeric complex 
containing binding sites for GABA, barbiturates, 
benzodiazepines, f3-carbolines and picrotoxinlike 
drugs (Olsen, 1981; Olsen and Leeb-Lundberg, 
1981). The structure of the GABA, receptor was 
recently deduced from cDNA clones and is com- 
posed of two a and two f3 peptide subunits which 
span the neuronal membrane to form a chloride 
channel (Schofield et al., 1987). GABA binds to the 
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receptor to open the chloride channel, resulting in 
membrane hyperpolarization and inhibition. 
Several convulsants, including bicuculline, picro- 
toxin, penicillin, D-tubocurarine, pentylenetetrazol 
(PTZ) and a-keto-6-guanidino-valeric acid have 
been shown to be GABA antagonists, blocking the 
inhibitory action of GABA by interacting with ei- 
ther GABA or picrotoxin binding sites (Curtis et al., 
1971; Curtis et al., 1972; Hill et al., 1972; Hill and 
Simmonds, 1973; Macdonald and Barker, 1978~; 
Johnston and Willow 1981; Olsen and Leeb- 
Lundberg, 1981; De Deyn et al., 1988). Benzodiaz- 
epine receptor ligands which were convulsant or 
proconvulsant, such as the P-carbolines PCCM, 
PCCE, and DMCM and the pyrazoloquinoline CGS 
82 16 reduced GABAergic inhibition through an al- 
losteric interaction with the GABAA receptor 
(Braestrup et al., 1983; Peterson, 1983). 
AED reduction of seizures induced in experimen- 
tal animals by either intravenous (i.v.) or subcuta- 
neous (s.c.) administration of PTZ has been used to 
predict antiabsence efficacy of drugs such as diaz- 
epam (DZP), trimethadione (TMO), sodium val- 
proate (VPA), and ethosuximide (ESM) (Swinyard, 
1969). The antiabsence AEDs were also effective 
against DMCM-induced seizures (Petersen, 1983). 
Experimental drugs also have an anticonvulsant ac- 
tion in experimental animals against PTZ or DMCM 
seizures. The pyrazoloquinoline, CGS 9896, was 
anticonvulsant in the PTZ test (Petrack et al., 1983), 
and the p-carboline, ZK 91296, was protective 
against PTZ- and DMCM-induced seizures (Pe- 
tersen et al., 1984; Klockgether et al., 1985). 
Enhancement of GABA-mediated inhibition has 
been proposed as the mechanism of action of sev- 
eral AEDs used extensively in human therapy (Ec- 
cles et al., 1963; Nicoll, 1972; Macdonald and 
Barker, 19786, 1979; Gent and Phillips, 1980; Shultz 
and Macdonald, 1981). Anticonvulsant benzodiaz- 
epines such as DZP directly enhance GABA re- 
sponses (Choi et al., 1977; Macdonald and Barker, 
19786), whereas VPA increases brain and synapto- 
soma1 GABA concentration (Godin et al., 1969; 
Simler et al., 1973; Iadarola and Gale, 1979). How- 
ever, although DZP has been shown to enhance 
GABA responses, no clear action of TMO [or its 
active metabolite, dimethadione (DMO)] VPA, or 
ESM on GABAergic inhibition at clinically relevant 
concentrations has been reported. 
In this study, we determined whether or not the 
antiabsence (ESM, DMO, VPA, and DZP) and two 
experimental (CGS 9896 and ZK 91296) AEDs had 
an action on postsynaptic GABA responses on 
mouse spinal cord neurons grown in primary disso- 
ciated cell culture at clinically re’cvant concentra- 
tions. We also determined the concentration- 
dependent effects of the convulsant drugs PTZ and 
DMCM on GABA responses and the effects of the 
AEDS on PTZ- and DMCM-induced reduction of 
GABA responses. 
MATERIALS AND METHODS 
Primary dissociated cell culture 
Cultures of spinal cord neurons were prepared 
from dissected spinal cords and attached dorsal root 
ganglia from 12-14-day-old fetal mice as described 
previously (Ransom et al., 1977). Experiments con- 
formed to the policy of the American Physiological 
Society. The tissue was minced and then mechani- 
cally dissociated by trituration in Ca2+- and 
M$+-free balanced salt solution to a suspension of 
single cells and small clumps. The dissociated cells 
were suspended in culture medium [W% Eagle’s 
miminal essential medium (MEM) supplemented 
with 5.5 g glucose and 1.5 g NaHCO,/L, 5% heat- 
inactivated horse serum, and 5% Nu-Serum I1 (Col- 
laborative Research) 325 mOsm] and then plated on 
sterile collagen-coated 35-mm dishes. The cultures 
were maintained in an incubator with an atmo- 
sphere of 93% room air and 7% CO, at 35°C. The 
bicarbonate/CO, buffer maintained pH at 7.4. 
5-Fluoro-2’deoxyuridine was added to the cultures 
on days 4-6 to suppress the growth of rapidly di- 
viding non-neuronal cells. Medium was changed 
twice weekly. Cultures were maintained for 4-9 




All recordings were made in a high magnesium 
ion concentration of Dulbecco’s phosphate- 
buffered saline (PBS) after removal of growth me- 
dium. The elevated magnesium ion concentration in 
the recording solution suppressed spontaneous syn- 
aptic and action potentials. The recording solution 
contained (in mM): NaCl 137, Na2HP04, 8.06, KCl 
2.68, KH2P04 1.47, CaCl, 1, MgCI, 10, and glucose 
5.6 (pH 7.4). Heavy paraffin oil was applied to the 
surface of the bathing solution to retard evapora- 
tion. 
Solutions of drugs were always prepared on the 
day of the experiment in the following manner: 
DMCM, DZP, and VPA were dissolved in dimeth- 
ylsulfoxide (DMSO) to form lo-, 1-, and 60-mM 
stocks, respectively. DMO, ESM, and PTZ were 
dissolved in recording solution to form 12-, 6-, and 
10-mM stocks, respectively. Aliquots were re- 
moved and diluted in bathing medium to obtain the 
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applied concentrations. The final solutions con- 
tained GO. 1% DMSO. 
DMCM was applied at concentrations between 1 
nM and 10 p M .  PTZ concentrations ranged be- 
tween 62.5 p M  and 10 mM. In the experiments test- 
ing the effects of AEDs on DMCM- and PTZ- 
induced reduction of GABA responses, DMCM 
was used at a concentration of 250 nM and PTZ was 
used at a concentration of 1 mM. The ranges of 
AED concentrations tested were determined from 
human clinical pharmacologic data when available. 
Concentrations equivalent to the clinically useful 
therapeutic range in CSF or comparable to the free 
levels in serum were used (Gugler et al., 1977; 
Eadie and Tyrer, 1980; Sherwin, 1982; Wilder and 
Karas, 1982). 
Experimental apparatus 
For experiments, the culture dish containing 
bathing solution was placed on a microscope stage 
heated by a Pellitier device with temperature regu- 
lated at 3435°C. The stage was mounted on a Leitz 
inverted microscope fitted with phase-contrast op- 
tics to facilitate micropipette placement (using Leitz 
micromanipulators) and to penetrate cells under di- 
rect visual control. 
Electrophysiologic recordings 
Intracellular recordings were made from the so- 
mata of spinal cord (>20 pm) neurons using glass 
micropipettes (25-50 Ma) filled with 3M KCI. Use 
of an active bridge circuit (Model 8100, Dagan, Min- 
neapolis, MN, U.S.A.) allowed simultaneous re- 
cording of membrane potential and injection of 
current (for steady-state polarization or periodic 
stimulation) using a single micropipette. The pream- 
plifier output signal was led to a six-channel poly- 
graph (Model 2600, Gould Instruments, Cleveland, 
OH, U.S.A.) for continuous recording. 
GABA responses 
GABA (0.5 M, pH 3.4) was applied iontophoret- 
ically using 500-ms duration rectangular current 
pulses at 5-s intervals. Tips of iontophoretic pi- 
pettes were positioned to within 2 pm of neuronal 
somata. The use of 3M KC1-filled micropipettes re- 
sulted in elevation of intracellular chloride ion con- 
centration and a shift in the chloride equilibrium 
potential from about -65 mV to about -20 mV. 
Under these conditions, an increase in chloride con- 
ductance resulted in an outward chloride current 
giving depolarizing GABA responses (Nowak et al., 
1982). Responses of -10-15 mV in amplitude were 
evoked following membrane hyperpolarization (to 
between -70 and -90 mV) to avoid saturation at 
or near the chloride equilibrium potential. 
Direct effects of convulsant drugs and AEDs on 
GABA responses were accepted only if the GABA 
responses returned to control amplitude within 5-10 
min of removal of the drug-containing micropipette. 
In the studies evaluating effects of coapplication of 
the AEDs and the convulsant drugs on GABA re- 
sponses, data were accepted only when the original 
direct effect of the convulsant drug could again be 
evoked after recovery of the GABA response from 
the combination effect. 
Drug application 
For evaluation of drug effects on GABA re- 
sponses, all drugs were applied by a perfusion mi- 
cropipette. A blunt-tipped (10-15 pm) micropipette, 
filed with the recording solution containing convul- 
sant or convulsant and AED, was positioned 15-30 
pm from the soma of the cell under study. The open 
end of the perfusion micropipette was connected to 
a pressure regulator, set between 0.4 and 0.8 psi, by 
tight-fitting polyethylene tubing. Pressure-pulse du- 
ration, regulated by a voltage-activated three-way 
valve, was 10 s. Under these conditions, local per- 
fusion produced no artifacts, and application of re- 
cording solution (with or without vehicle) was vir- 
tually free of effects. When the effect of coapplica- 
tion of convulsant drugs and AEDS was studied, 
the drugs were applied through one perfusion mi- 
cropipette to avoid flow artifacts. The concentra- 
tions reported in this study are those contained in 
the perfusion micropipettes. Although some reduc- 
tion in the concentration of drug at the neuron may 
have occurred due to dilution in the surrounding 
medium, increasing durations of application or al- 
tering the position of the perfusion micropipette did 
not increase the effects of the drugs. Thus, although 
there may be some small inaccuracy in the drug 
concentrations, the reported concentrations are 
probably close to those at the surface of the neuron. 
The perfusion micropipettes and recording mi- 
cropipettes were held by Leitz micromanipulators. 
To decrease leakage of drugs into the bathing me- 
dium, the tips of the perfusion micropipettes were 
kept in the oil phase between drug application trials. 
They were lowered in the aqueous phase only when 
drug application was desired. 
mgs 
CGS 9896 [2-(p-chlorophenyl)-2,5-dihydro- 
pyrazolo)-4,3-C)quinolin-3(5H)-11 was obtained 
from Ciba-Geigy (Summit, NJ, U.S.A.). DZP was 
obtained from Hoffman-LaRoche (Nutley, NJ, 
U.S.A.). ZK 912% (ethyl 5-benzyloxy4methoxy- 
methyl-p-carboline-3-~-carboxylate) and DMCM 
(methyl-6,7-dimethoxy4ethyl-~-carboline-3-~arb0x- 
ylate) were obtained from A / S  Ferrosan (Denmark). 
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DMO (5,5-dimethyl-2,4-oxazolidine-dione), PTZ 
(6,7,8,9-tetrahydro-SH-tetrazoIo-[ 1,5-a]azepine), 
and GABA were purchased from Sigma Chemical 
(St. Louis, MO, U.S.A.). VPA and ESM were ob- 
tained from Parke-DavidWarner-Lambert Re- 
search Laboratories (Ann Arbor, MI, U.S.A.). 
Algebraic and statistical methods 
Mean values and SD were calculated for GABA 
response amplitudes before, during, and after drug 
application. Mean values and SD for the effects of 
the coapplied convulsant drugs and AEDs on 
GABA responses were also calculated. 
All effects were expressed as percentage of 
change in GABA response from control GABA re- 
sponse. The statistical significance of differences 
between GABA responses with and without drug 
application was calculated using the two-tailed Stu- 
dent's t test; p < 0.05 was considered statistically 
significant. 
RESULTS 
Direct effects of convulsant drugs PTZ and DMCM 
on GABA responses 
Application of PTZ or DMCM to spinal cord neu- 
rons did not alter resting membrane potential or 
conductance. Application of recording solution 
(with or without vehicle) (n = 10) did not signifi- 
cantly alter GABA responses (100.8 k 1.9%). 
PTZ and DMCM rapidly and reversibly reduced 
GABA responses. The PTZ effect was concentra- 
tion-dependent (Fig. 1). A si&icant 6.2 -+ 2.1% 
decrease of GABA responses (p < 0.001) was ob- 
tained at 125 ptf, and complete inhibition was ob- 
tained at 10 mM. The DMCM effect was also con- 
centration dependent (Fig. 2). A significant 9.9 * 
2.3% decrease of GABA responses (p < 0.001) was 
found at 10 nM. The inhibition of GABA responses 
reached a maximum of 39% at 1 FM. Although both 
PTZ and DMCM reduced GABA responses, 
DMCM was more potent than PTZ. The estimated 
ICs0 values for the inhibition of GABA responses 
were 1.1 mM for PTZ and 33 nM for DMCM. 
Direct effect of the AEDs on GABA responses 
ESM (600 and 1,200 wICI) ,  DMO (2 and 6 mM), 
CGS 98% (2 pV), and ZK 912% (2 plf) did not 
alter GABA responses significantly (Table 1). VPA 
(200 produced a small (2.1%) but significant 
reduction of GABA responses. DZP applied at con- 
centrations between 1 and 500 nM enhanced GABA 
responses in a concentration-dependent manner. 
For DZP, a significant 12.6 f 3.4% enhancement of 
GABA responses (p < 0.001) was obtained at 10 
nM, and a peak enhancement of 82.4 k 5.7% was 
obtained at 500 nM (Table 1). 
Effects of AEDs on FTZ-induced antagonism of 
GABA responses 
The reduction of GABA responses produced by 
PTZ (1 mM) was unaltered by ESM (600 pM) and 
DMO (2 and 6 mM) (Table 2). Similarly, the benzo- 
diazepine receptor antagonists, CGS 9896 (1 pV) 
and ZK 91296 (1 phi), did not alter PTZ (1 mM) 
reduction of GABA responses Vable 2 and Fig. 4A 
and B). VPA (200 FM), however, coapplied with 
PTZ (1 mM), slightly enhanced (p < 0.05) the in- 





flG. 1. Concentration-dependent 
effects of pentylenetetrazol (PTZ) 
on GABA responses on spinal cord 
neurons. GABA responses (bot- 
tom) show the effect on one cell of 
the respective concentrations of 6 
applied PTZ. Initial control (CTL) % 
GABA response shows a stable re- 
sponse before drug application. ,$ - 
GABA responses returned to con- 
trol values within 2 min after re- --60 - 
moval of PTZ. lontophoretic GABA 
application is indicated by a dash. 0 --70 - 
Effects are expressed as percent- 
age of change of the original GABA 
response. Data are means plus SD 
of responses from 3 to 13 neurons. 
SD shown in one direction only. "p 
< 0.001 from control GABA re- 
sponses. Drug concentrations 
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FIG. 2. Concentration-depend- 
ent effects of methyl-6,7- 
dimethoxy-4-ethyl-p-carboline- 
3-carboxylate (DMCM) on GABA 
responses on spinal cord neu- 
rons. GABA responses (bottom) X 
show the effect on one cell of 5 
the respective concentrations 0" 
(CTL) shows a stable GABA re- 2 
sponse before drug application. 9 
GABA responses returned to 
control values within 10 min af- O 
ter removal of the DMCM- % -30- 
containing micropipette. lonto- E 
phoretic GABA application is in- 5 
dicated by a dash. Effects are f: 
expressed as percentage of 
change of the original GABA re- 
sponse. Data are means plus SD 
of responses from 5 to 15 neu- 
rons. SD shown in one direction 
only. "p < 0.001 from control 
GABA responses. Drug concen- 
logarithm molar. 
- 1 0  - 
of applied DMCM. Initial control ? -20 - 
,I I I I 
-9 - 8  -7 -6 -5 
trations shown on abscissa are Drug Con< log (M) 
In contrast, DZP with a threshold concentration 
of 10 nM (p < 0.05) significantly reversed the FTZ- 
induced reduction of GABA responses. Coapplica- 
tion of PTZ (1 mM) and DZP (100 nM) resulted in a 
signifcant 7.4 & 5.3% enhancement of the GABA 
response (p < 0.001) (Table 2 and Fig. 3A). 
Effects of AEDs on DMCM-induced decreases of 
GABA responses 
DMCM (250 nM) reduction of GABA-responses 
was unaltered by ESM (600 pM), DMO (2 mM), or 
VPA (200 CLM) (Table 3). Coapplication of DZP, 
CGS 9896 or ZK 91296, however, influenced the 
DMCM-induced inhibition of GABA-responses 
(Table 3). CGS 9896 (2 p M )  and ZK 91296 (2 CLM) 
TABLE 1. Direct eflects of AEDS on GABA responses 
GABA response 
No. of cells (% control 
AED studied (n) f SEM) 
ESM 6OOJLM 8 102.3 2 3.3 
ESM 1,200 JLM 5 100.4 2 2.1 
DMO 
2 m M  3 99.3 ? 1.7 
6 m M  4 99.3 2 1.4 
VPA 200 )LM 8 97.9 2 1.7" 
CGS 98% 2 pM 10 100.2 ? 4.6 
ZK 912% 2 pM 6 100.3 2 2.7 
DZP 
1nM 5 100.1  2 1.2 
10 nM 5 112.6 ? 3.4' 
100 nM 38 143.7 ? 17.2' 
500 nM 5 182.4 2 5.7' 
a p < 0.01, 'p < 0.001, from control, Student's two-tailed f 
AED, antiepileptic drug; ESM, ethosuximide; DMO, 
test. 
dimethadione; VPA, sodium valproate; DZP, diazepam. 
significantly antagonized the DMCM-induced inhi- 
bition of GABA responses (Table 3 and Fig. 4C and 
D). DZP, with a threshold concentration of 10 nM 
(p < 0.05), significantly reversed the DMCM- 
induced inhibition of GABA responses (Fig. 3B). 
Simultaneous application of DMCM 250 nM and 
DZP 500 nM resulted in a small increase (5.5%) in 
GABA responses compared to control responses 
(Table 3). 
TABLE 2. Efiecrs of AEDS on PTZ-induced 
antagonism of GABA responses 
No. of GABA 
cells response 
studied (% control 
AED (n) rt SEM) 
F T Z l m M  
P T Z I m M + E S M 6 0 0 @  
F T Z l m M  
PTZ 1 mM + DM 2 mM 
FTZlmM 
PTZ 1 mM + D M 0 6 m M  
F T Z l m M  
PTZ 1 mM + CGS 98% 1 )LM 
P T Z l m M  
FTZ 1 mM + ZK912% 1 )LM 
F T Z l m M  
FTZl mM + VPA200uM 
FTZlmM 
FTZ 1 mM + DZP 1 nM 
F T Z I m M  
FTZ 1 mM + DZP 1 O n M  
FTZImM 
PTZ I mM + DZP 100nM 
PTZlmM 











60.2 2 7.4 
61.3 rt 5.8 
61.9 2 3.8 
62.4 2 5.4 
58.0 2 5.6 
59.1 rt 11.1 
66.3 2 8.9 
67.3 2 8.4 
62.3 rt 7.2 
61.0 rt 11.6 
60.0 2 6.2 
57.8 2 5.4" 
63.2 rt 7.2 
61.5 2 8.5 
67.6 5 6.2 
70.6 2 4.7' 
107.4 2 5.3' 
57.6 f 9.0, 
126.8 rt 8.1 
64.0 t 6.3 
Abbreviations as in Table I .  
p < 0.05, 'p < 0.001 from FTZ 1 mM, Student's 2-tailed r 
test, paired samples. 
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FIO. 3. Blockade of pentylenetetra- 
zol (PTZ 1 mM) (panel A) and DMCM 
(250 nM) (panel B) -induced reduc- 
tion of GABA responses on spinal 
cord neurons by DZP (10, 100, and 
500 nM). Column 2 shows PTZ and 
methyl 6,7-dimethoxy-4-ethyl-p- 
carboline-3carboxylate (DMCM) ef- 
fects. Columns 3-5 show effects of 
simultaneous convulsant and diaze- 
pam (DZP) applications. Columns 1 
and 6 show control (CTL) GABA re- 
sponses before and after drug appli- 
cations, respectively. Control re- 
sponses between drug .applications 
are not shown. lontophoretic GABA 
application is indicated by a dash. 
DISCUSSION 
C T L  P T Z  l m h f  P T Z  1 m M  P T Z  1 m M  P T Z  1 m M  CTL 
+ D Z  1 0 n M  + D Z  l O O n l I  + DZ 500nU 
- 
CABb 
C T L  DMChl 2 5 0 n M  DMCM 2 5 0 n M  DMCM 250nXI DUCM 2 5 0 n J f  C T L  
+ D Z  10nU + D Z  1 0 0 n M  + D Z  5 0 0 r ~ X f  
B. nn 
1 2 
To understand the mechanism(s) of action of 
antiabsence AEDs better, we investigated the ef- 
fects of some clinically and/or experimentally 
proven AEDs on GABA responses recorded from 
mouse spinal cord neurons in cell culture. The ef- 
fects of two convulsant drugs used in chemical an- 
imal models of epilepsy, PTZ and DMCM, were 
studied as well. Furthermore, the possible antago- 
nistic effect of the AEDS on PTZ- and DMCM- 
induced reduction of GABA responses was deter- 
mined. 
The convulsant drugs PTZ and DMCM reduced 
GABA responses in a concentration-dependent 
manner, consistent with previous observations 
(Pellmar and Wilson, 1977; Macdonald and Barker, 
1978~; Jensen and Lambert, 1983; Skerritt and 
Macdonald, 1984). This reduction of postsynaptic 
GABAergic inhibition might underlie the convul- 
sant activity of these drugs. Our results also con- 
firm that DMCM exerts its effect on GABA re- 
sponses through an interaction with the benzodiaz- 
epine receptor. Indeed, the benzodiazepine 
receptor antagonists CGS 9896 and ZK 91296 (De 
Deyn and Macdonald, 1987) completely antago- 
nized the DMCM effect. DMCM is an inverse ago- 
nist at the benzodiazepine receptor (Jensen and 
Lambert, 1983; Skerritt and Macdonald, 1984), 
which probably explains the protective activity of 
ZK 912% against DMCM-induced seizures (Klock- 
gether et al., 1985). PTZ, however, was previously 
demonstrated to inhibit GABA responses through 
an interaction with a different site on the GABA 
receptor, possibly the picrotoxin receptor (Macdon- 
ald and Barker, 1977, 1978~). 
The anticonvulsants ESM, DMO, and VPA ap- 
3 4 5 6 
CTL PTL ImU CTL PTZ ImY CTL 
+ ZK 91296 
L*HA 
fTL PTZ ImM CTL PTZ lmbl CTL 
CTL DMUCY 250nY CTL DYCY 250nY CTL 
t ZK 91296 
CTL DYCM 25OnM CTL DYCY 250nM CTL 
t CGS 9896 
I 2 3 I 5 
FIG. 4. Lack of antagonism of pentylenetetrazol (PTZ 1 mM) 
and antagonism of methyl-6,7-dimethoxy-4-ethyl-p-car- 
boline-3-carboxylate (DMCM 250 nM)-induced reduction of 
GABA-responses on spinal cord neurons by ZK 91296 (2 pM, 
panels A and C) and CGS 9896 (2 pM, panels B and D). Col- 
umn 2 shows the PTZ and DMCM effect. Column 4 shows the 
effect of simultaneous convulsant and experimental antiepi- 
leptic drug (AED) applications. Columns 1, 3, and 5 show 
control (CTL) responses, respectively, before, between, and 
after drug applications. lontophoretic GABA application is 
indicated by a dash. 
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TABLE 3.  Effects of AEDS on DMCM-induced 










DMCM 250 nM 
DMCM 250 nM + ESM 600 FM 
DMCM 250 nM -. . -. . - . .- . 
DMCM 250 nM + DMO 2 mM 
DMCM 250 nM 
DMCM 250 nM + VPA 200 
DMCM 250 nM 
DMCM 250 nM + DZP 10 nM 
DMCM 250 nM 
DMCM 250 nM + DZP 100 nM 
DMCM 250 nM 
DMCM 250 nM + DZP 500 nM 
DMCM 250 nM 
DMCM 250 nM + CGS 98% 2 phi 
DMCM 250 nM 
DMCM 250 nM + ZK 912% 2 phi 
62.4 t 5.8 
64.5 t 7.0 
60.6 t 3.6 
57.8 t 3.3 
62.3 2 4.4 
61.7 t 6.4 
58.7 t 4.0 
63.3 t 4.1" 
60.5 t 5.5 
71.7 t 13.4" 
58.7 t 2.6 
63.0 2 6.5 
105.5 t 9.96 
99.0 2 1.3' 
59.2 2 5.5 
99.2 k 3.6' 
Abbreviations as in Table 1. 
p c 0.05, bp < 0.001 from DMCM 250 nM, Student's two-tailed f test, 
paired samples. 
plied at concentrations equivalent to the clinically 
useful therapeutic range in cerebrospinal fluid 
(CSF), did not alter GABA responses. Moreover, 
these drugs did not alter neuronal membrane poten- 
tial or input resistance. These results confirm pre- 
vious findings for ESM and VPA (Barnes and Dich- 
ter, 1984; Macdonald et al., 1984; Macdonald et al., 
1985; McLean and Macdonald, 1986; Buchalter and 
Dichter, 1986). At higher concentrations, however, 
previous studies demonstrated an enhancement of 
GABA responses by VPA (Macdonald and Bergey, 
1979; Harrison and Simmonds, 1982). The observed 
concentration-dependent effect of DZP on GABA 
responses with a maximal direct effect of 82.4% is 
consistent with previous findings (Choi et al., 1977; 
Macdonald and Barker, 19786; Skemtt et al., 1984). 
The two experimental AEDs CGS 9896 and ZK 
91296, however, applied at a concentration of 2 pM 
remained inactive in this paradigm. This finding is 
consistent with previous work describing CGS 98% 
and ZK 91296 to be pure antagonists at the benzo- 
diazepine receptor (De Deyn and Macdonald, 
1987). 
With the exception of DZP, none of the tested 
AEDs antagonized or reversed PTZ-induced inhibi- 
tion of GABA responses. The applied PTZ concen- 
tration (1 mM) was comparable to the critical brain 
PTZ level for onset of seizures in mice (Yonekawa 
et al., 1980). Behavioral studies, however, demon- 
strated the protective action of VPA, DMO, ESM, 
CGS 98%, and ZK 91296 against PTZ-induced sei- 
zures (Chen et al., 1963; Krall et al., 1978; Petrack 
et al., 1983; Petersen et al., 1984). DZP (100 nM) 
coapplied with PTZ (1 mM) reversed the inhibition 
of GABA responses. This is consistent with behav- 
ioral findings for this benzodiazepine receptor ago- 
nist (Haefely et al., 1981). 
Neither VPA, DMO, nor ESM antagonized 
DMCM-induced reduction of GABA responses. 
DZP, however, antagonized the DMCM-induced in- 
hibition of GABA responses. This is probably due 
to its high-affinity binding at the benzodiazepine re- 
ceptor in competition with DMCM (Haefely et al., 
1981). CGS 98% and ZK 91296, although devoid of 
any intrinsic effect, completely antagonized the 
DMCM-induced reduction of GABA responses. 
This is explained by the previously demonstrated 
antagonistic effect of these compounds at the ben- 
zodiazepine receptor (De Deyn and Macdonald, 
1987). The demonstrated antagonism of the DMCM 
effect might be the underlying mechanism for the 
protective action against DMCM-induced seizures 
for ZK 91296 (Klockgether et al., 1985). 
The lack of effects of VPA, ESM, and DMO on 
postsynaptic GABA action contrasts with their clin- 
ical efficacy against generalized absence seizures, 
and suggests that direct postsynaptic enhancement 
of GABAergic inhibition is not a common mecha- 
nism of action of antiabsence AEDs. These results 
also suggest that the disturbance responsible for 
generalized absence seizures may not be localized 
to the GABA receptor. Alternatively, the therapeu- 
tic efficacy of these AEDs may be due to the stim- 
ulation of GABA synthesis andor the inhibition of 
GABA metabolism as has been shown for VPA 
(Volzke and Doose, 1973; Hammond and Wilder, 
1985). Finally, there may be alterations in patholog- 
ic neurons, and their interactions may not have 
been present in our neurons in culture. 
Our results suggest that DZP most probably ex- 
erts its antiabsence effect by enhancing GABA- 
mediated inhibition through an interaction with the 
benzodiazepine receptor. CGS 98% and ZK 912%, 
two experimentally proved AEDs, were shown to 
be pure antagonists at the benzodiazepine receptor. 
Their anticonvulsant effect against DMCM-induced 
seizures can be explained by their benzodiazepine 
receptor antagonistic effect. Their mechanism 
against PTZ-induced seizures is less clear. The ex- 
istence of an endogenous benzodiazepine receptor 
inverse agonist has been proposed (Guidotti et al., 
1982). CGS 9896 and ZK 91296 could enhance 
GABAergic inhibition by displacing this endoge- 
nous compound. Regardless of mechanism of ac- 
tion, CGS 98% and ZK 912% may be clinically use- 
ful AEDs. 
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RESUMEN 
Los mecanismos de acci6n de las medicaciones antiepiltpticas 
eficaces contra 10s ataques generalizados de ausencia (AEDs 
antiausencia) permanecen inciertos. Los AEDs antiausencia 
son, generalmente, eficaces contra ataques experimentales indu- 
cidos por el pentilentetrazol (PTZ) y el metil-6,7-dimetoxy-4-etil- 
pcarbolina-3-carboxilato (DMCM) en animales, medicaciones 
que reducen la inhibicibn GABAfrgica. Hemos estudiado 10s 
efectos de varios AEDs sobre respuestas-GABA registradas en 
las neuronas de la mfdula espinal de ratones que habian crecido 
en cultivos de celulas primarieas disociadas. Cuatro AEDs an- 
tiausencia fueron incluidos: etoxusimida (ESM), dimetadiona 
(DMO), valproato s6dico (VPA) y diazepan (DZP). Tambitn se 
incluyeron dos AEDs experimentales, CGS 98% y ZK 912%, 
con acci6n anticonvulsiva contra 10s ataques inducidos por PTZ 
o DMCM. Tambifn se valoraron 10s posibles efectos de 10s 
AEDs antiausencia y experimentales sobre el PTZ y la inhibici6n 
de las respuestas-GABA inducidas por el DMCM. El PTZ y el 
DMCM redujeron las respuestas-GABA de modo reversible y 
dependiendo de sus concentraciones. El PTZ inhibi6 cmpleta- 
mente las respuestas-GABA a 10 mM (ICs0 de 1.1 mM) mientras 
que la inhibici6n de las respuestas GABA inducida por el DMCM 
alcanz6 un nivel estable del39% de 10s valores control con I pM 
(lC50 de 33 mM). La ESM (1200 pM), la DMO (6 mM), el VPA 
(200 pM), el CGS 98% (2 pM) y el ZK 98% (2 pM) no alteraron 
las respuestas-GABA. El DZP aument6 las respuestas GABA de 
una manera concentraci6n-dependiente. La inhibici6n de las re- 
spuestas-GABA producidas por el PTZ (1 mM), no se alter6 con 
las ESM (600 pM), la DMO (6 mM), el CGS 98% (1 pW o el ZK 
98% (1 pM). La co-aplicacion de VPA (200 pM) y el PTZ (1 mM) 
aument6 ligeramente 10s efectos del PTZ. Sin embargo el DZP 
(>lo nM) revirti6 la reducci6n de las respuestas GABA induci- 
das por el PTZ. La reducci6n de las respuestas GABA producida 
por el DMCM (250 nM) no fue alterada por la ESM (600 pM), la 
DMO (2 mM) o el VPA (200 m. Sin embargo el CGS 98% 
(2 pM), y el ZK 912% (2 pM), antagonizaron el efecto del 
DMCM. El DZP (>I0 nM) revirti6 significativamente la inhibi- 
ci6n de las respuestas GABA inducidas por el DMCM. La falta 
de efectos de CPA, ESM y DMO sobre las respuestas GABA 
post-sinlpticas sugiere que el incremento de la acci6n GABA 
post-sinlptica no es un mecanismo comdn de actuaci6n de las 
AEDs antiausencia. Todas las AEDs DZP, CGS 98% y ZK 912% 
revirtieron la reducci6n de las respuestas GABA producidas por 
el DMCM per0 no las inducidas por el PTZ lo que sugiere que 
estos AEDs bloquean 10s ataques DMCM actuando sobre 10s 
receptores de la benzodiazepina. Sin embargo, puesto que el 
incremento de las respuestas GABA s6lo se produce por el DZP, 
permanece todavia sin aclarar el por q u t  el CGS 98% y el ZK 
912% bloquean 10s ataques producidos por el PTZ. 
(A. Portera-Slnchez, Madrid) 
ZUSAMMENFASSUNG 
Der Wirkmechansimus von Antiepileptika gegen generalisierte 
Absencen ist unklar. Antiabsencemittel sind generell wukungs- 
voll gegen PTZ- und Methyl-6,7-Dimethoxy-4-Athyl- 
p-Carbolin-3-Carboxylat (DMCM) induzierte tierexpenmentelle 
Anfdle, also von Medikamenten, die die GABA-erge Inhibition 
reduzieren. Es wurde vermutet, dap Antiabsencemittel die 
GABA-erge Inhibition verstarken. Wir untersuchten die 
Wirkung von verschiedenen Antiepileptika auf GABA- 
Antworten in spinalen Mauseneuronen, die in Zellkulturen gew- 
achsen waren. Es wurden 4 Absencemittel untersucht: Ethosux- 
imid (ESM), Dimethadion (DMD), Sodium Valproat (VPA) und 
Diazepam (DZP). Zusatzlich wurden 2 experimentelle Antiepi- 
leptika, CGS 98% und ZK 912%, die gegen PTZO oder DMCM- 
induzierte Anfalle wirkungsvoll sind, eingeschlossen. Mogliche 
Wirkungen der Antiabsence- und experimentellen Antiepileptika 
auf PTZ- und DMCM-induzierte Hemmung der GABA- 
Antworten wurden ebenfalls ausgewertet. PTZ und DMCM 
zeigten eine konzentrationsabhlngige reversible Reduktion der 
GABA-Antworten. PTZ zeigte eine komplette Hemmung der 
GABA-Antworten bei 10 mM (IC50 1,l mM), DMCM-Hemmung 
der GABA-Antworten zeigte ein Plateau von 39% der Kontroll- 
werte bei 1 p M  (IC, von 33 mM). ESM (1200 M, DMD (6 mM), 
VPA (200 pM) ,  CGS 98% (2 pM) und ZK 98% (2 pM) anderten 
nicht die GABA-Antworten. DZP verstarkte die GABA- 
Antworten konzentrationsabhangig. Die durch PTZ (1 mM) 
hervorgerufene Hemmung der GABA-Antworten war bei ESM 
(600 pM), DMD (6 mM), CGS 98% (1 mM) und ZK 3836 (1 mM) 
unveriindert. Zusatliche Anwendung von VPA (200 mM) und 
PTZ (1 mM) verstarkten geringfiigig den PTZ-Effekt. DZP 
(10 nM) kehrte die durch FTZ hervorgerufene Reduktion der 
GABA-Antworten um. Die durch DMCM (250 nM) hervorg- 
erufene Hemmung der GABA-Antworten war durch ESM 
(600 pM), DMD (2 mM) und VPA (200 pkf) unbeeinflusst. CGS 
98% (2 phf) und ZK 912% (2 fl antagonisierten die DMCM- 
Wirkung. DZP (>lo nM) kehrte die durch DMCM-induzierte 
Hemmung der GABA-Antworten um. Das Fehlen einer Wirkung 
von VPA. ESM und DMD auf die postsynaptischen GABA- 
Antworten legen nahe, dap eine direkte Verstarkung der 
postsynaptischen GABA-Aktion kein gemeinsamer Mechanis- 
mus der Antiabsencemittel darstellt. Die Antiepileptika DZP, 
CGS 98% und ZK 912% kehrten die DMCM-Wirkung auf die 
GABA-Antworten urn, jedoch nicht die von PTZ, was vermuten 
Iapt, dap diese Antiepileptika die DMCM-Anfalle iiber die 
Wirkung an den Benzodiazipin-Rezeptren verhinderte. Da je- 
doch nur DZP GABA-Antworten verstarkte, ist unklar, in 
welcher Weise CGS 98% und ZK 912% die PTZ-Anfiitle ver- 
hinderten. 
(C. Benninger, Heidelberg) 
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